Health Insurance (Pathology Services Table) Amendment Regulations 2007 (No. 2) (Cth)
Health Insurance (Pathology Services Table) Amendment Regulations 2007 (No. 2)1
Select Legislative Instrument 2007 No. 101
I, PHILIP MICHAEL JEFFERY, Governor‑General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973.
Dated 26 April 2007
P. M. JEFFERY
Governor‑General
By His Excellency’s Command
TONY ABBOTT
Minister for Health and Ageing
-
Name of Regulations
These Regulations are the Health Insurance (Pathology Services Table) Amendment Regulations 2007 (No. 2).
-
Commencement
These Regulations commence on 1 May 2007.
-
Amendment of Health Insurance (Pathology Services Table) Regulations 2006
Schedule 1 amends the Health Insurance (Pathology Services Table) Regulations 2006.
Schedule 1 Amendments
(regulation 3)
[1] Schedule 1, Part 2, subrule 1 (1), after definition of patient episode
insert
receiving APP, in relation to a patient episode, means an approved pathology practitioner in an approved pathology authority who:
(a)receives a request from a referring APP to render a designated test or tests; and
(b)renders each test included in the designated test that the referring APP has not performed.
[2] Schedule 1, Part 2, subrule 1 (1), after definition of recognised pathologist
insert
referring APP, in relation to a patient episode, means an approved pathology practitioner in an approved pathology authority who:
(a)has been requested to render one or more designated tests; and
(b)is unable, because of the lack of facilities in, or expertise or experience of the staff of, the laboratory of the authority, to render 1 or more of the tests included in the designated test; and
(c)requests a receiving APP in another approved pathology authority to render:
(i)the test or tests that the approved pathology practitioner is unable to render; or
(ii)all of the tests that are included in the designated test; and
(d)renders each test included in the designated test, other than the test or tests in respect of which the request mentioned in paragraph (c) is made.
[3] Schedule 1, Part 2, rule 6
substitute
-
Referral of designated tests by 1 pathology practitioner to another
(1)In this rule:
designated test means a pathology test relating to a patient episode that is a test of a kind described in item 65150, 65175, 66650, 66695, 66711, 66722, 66785, 66800, 66812, 66819, 66825, 69384, 69494, 71089, 71153 or 77165.
(2)This rule applies where 1 or more designated tests are referred by a referring APP to a receiving APP in another approved pathology authority.
(3)If a referring APP has rendered 1 or more designated tests:
(a)the amount specified in item 65150, 65153, 65175, 65176, 65177, 65178, 66650, 66695, 66698, 66701, 66704, 66707, 66711, 66722, 66725, 66728, 66731, 66785, 66800, 66803, 66812, 66819, 66825, 69384, 69387, 69390, 69393, 69396, 69494, 69495, 71089, 71091, 71153, 71155, 71157, 77165, 71166 or 71167 (as the case may be) is payable for each designated test rendered by the referring APP; and
(b)subject to subrule (5), the amount specified in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case may be) is payable for each designated test rendered by the receiving APP.
(4)If a referring APP has not rendered a designated test:
(a)for the first designated test that is rendered by the receiving APP — the amount specified in item 65157 65180 66651 66696, 66714, 66723, 66789, 66804, 66816, 66820, 66826, 69400, 69497, 71090, 71154 or 71169 (as the case may be) is payable; and
(b)for each subsequent designated test (if any) that is rendered by the receiving APP — subject to subrule (6), the amount specified in item 65158, 65181, 66652, 66697, 66715, 66724, 66790, 66805, 66817, 66821, 66827, 69401, 69498, 71092, 71156 or 71170 (as the case may be) is payable for each test rendered.
(5)For paragraph (3) (b), the maximum number of designated tests for which the fee mentioned in the relevant item is payable is as follows:
(a)for item 66652, 66715, 66790, 66817, 66821 or 66827 —
(b)for item 65158, 66805, 69498 or 71092 —
(c)for item 71156 or 71170 —
(d)for item 65181 or 66724 —
(e)for item 66697 or 69401 —
where:
X is the number of designated tests rendered by a referring APP.
(6)For paragraph (4) (b), the maximum number of designated tests for which the fee mentioned in the relevant item is payable is as follows:
(a)for item 66652, 66715, 66790, 66817, 66821 or 66827 — 1;
(b)for item 65158, 66805, 69498 or 71092 — 2;
(c)for item 71156 or 71170 — 3;
(d)for item 65181 or 66724 — 4;
(e)for item 66697 or 69401 — 5.
(7)Items in Group P10 (Patient episode initiation) do not apply to a receiving APP in subrule (2).
[4] Schedule 1, Part 2, paragraphs 14 (2) (b), (c) and (d)
substitute
(b)the service is rendered to a public patient at a recognised hospital.
[5] Schedule 1, Part 2, subrule 14 (9)
omit
item 73921
insert
item 73940
[6] Schedule 1, Part 2, rule 15
omit each mention of
item 73921
insert
item 73940
[7] Schedule 1, Part 2, paragraph 16 (2) (c)
substitute
(c)both approved pathology authorities are corporations and are connected entities within the meaning of the Corporations Act 2001; or
[8] Schedule 1, Part 2, subrule 18 (1)
substitute
(1)In this rule:
general practitioner has the meaning given by subrule 18A (1).
set of pathology services has the meaning given by subrule 18A (2).
[9] Schedule 1, Part 2, after rule 18
insert
18AMeaning of general practitioner and set of pathology services
(1)In rule 18:
general practitioner means a medical practitioner who:
(a)is not a consultant physician in any specialty; and
(b)is not a specialist in any specialty.
(2)In rule 18 and subject to subrule (3):
set of pathology services means a group of pathology services:
(a)that consists of services that are described in at least 4 different items; and
(b)all of which are requested in a single patient episode; and
(c)each of which relates to a patient who is not an admitted patient of a hospital.
(3)In rule 18, an item mentioned in this subrule is to be excluded from a set of pathology services:
(a)if a service is requested by an approved pathology practitioner of an approved pathology authority and rendered by another approved pathology practitioner of an approved pathology authority that is not related to the approved pathology authority of the first mentioned approved pathology practitioner — item 65079, 65082, 65157, 65158, 65166, 65180, 65181, 66606, 66609, 66639, 66642, 66651, 66652, 66663, 66666, 66696, 66697, 66714, 66715, 66723, 66724, 66780, 66783, 66789, 66790, 66792, 66804, 66805, 66816, 66817, 66820, 66821, 66826, 66827, 69325, 69328, 69331, 69379, 69383, 69400, 69401, 69419, 69451, 69489, 69492, 69497, 69498, 69500, 71076, 71090, 71092, 71096, 71148, 71154, 71156, 71169, 71170, 73309, 73312, 73315, 73318 or 73321; or
(b)an item in Group P10 (Patient episode initiation), Group P11 (Specimen referred) or Group P12 (Management of bulk‑billed services).
(4)An approved pathology authority is related to another approved pathology authority for paragraph (3) (a) if:
(a)both approved pathology authorities are employed (including employed under contract) by the same person, whether or not the person is also an approved pathology authority; or
(b)either of the approved pathology authorities is employed (including employed under contract) by the other; or
(c)both approved pathology authorities are corporations and are connected entities within the meaning of the Corporations Act 2001; or
(d)the approved pathology authorities are partners (whether or not either or both of the approved pathology authorities are individuals and whether or not other persons are in partnership with either or both of the approved pathology authorities); or
(e)both approved pathology authorities are operated by the Commonwealth or an authority of the Commonwealth; or
(f)both approved pathology authorities are operated by the same State or internal Territory or an authority of the same State or internal Territory.
[10] Schedule 1, Part 2, rule 19
omit
For item 69444:
insert
For items 69499 and 69500:
[11] Schedule 1, Part 2, rule 20
omit
For item 73317:
insert
For items 73317 and 73318:
[12] Schedule 1, Part 2, subrule 22 (1)
substitute
(1)For this rule:
metal toxicity testing group means items 66825, 66826, 66827 and 66828.
nutritional metals testing group means items 66819, 66820, 66821 and 66822.
[13] Schedule 1, Part 2, rule 25
substitute
-
Limitation on certain items
(1)For any particular patient, item 69336 is applicable not more than once in each period of 7 days.
(2)For any particular patient, each of items 66819, 66820, 66821, 66822, 66825, 66826, 66827 and 66828 is applicable not more 3 times in a 6 month period.
(3)For any particular patient, the following items are applicable not more than once in a 12 month period:
(a)items 66655 and 66659;
(b)item 69491 or 69492;
(c)item 69499 or 69500.
(4)For any particular patient, the following items are applicable not more than twice in a 12 month period:
(a)items 66539, 71075, 71127, 71135 and 71137;
(b)item 66605 or 66606;
(c)item 69488 or 69489.
(5)For any particular patient, each of items 66551, 69445, 69451, 71079, 73314, 73315 and 73523 is applicable not more than 4 times in a 12 month period.
(6)For any particular patient, each of items 66554 and 71077 is applicable not more than 6 times in a 12 month period.
(7)For any particular patient, item 66626 is applicable not more than 36 times in a 12 month period.
(8)For any particular patient, item 69418 or 69419 is applicable not more than twice in a 24 month period.
(9)For any particular patient, item 66750 or 66751 is applicable not more than once in a pregnancy.
[14] Schedule 1, Part 2, rule 26
omit
item 69364, 69365 or 69367
insert
item 69316, 69317, 69319, 69494, 69495, 69496, 69497 or 69498
[15] Schedule 1, Part 2, rule 27
omit
item 73320
insert
item 71148, 73320 or 73321
[16] Schedule 1, Part 3, after item 65078
insert
| 65079 |
A test described in item 65078 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
91.75 |
[17] Schedule 1, Part 3, after item 65081
insert
| 65082 |
A test described in item 65081 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
98.25 |
[18] Schedule 1, Part 3, items 65096 to 65111
substitute
| 65096 |
Blood grouping (including back‑grouping if performed), and examination of serum for Rh and other blood group antibodies, including: (a) identification and quantitation of any antibodies detected; and (b) (if performed) any test described in item 65060 or 65070 |
41.65 |
| 65099 |
Compatibility tests by crossmatch — all tests performed on any 1 day for up to 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090 or 65096 (Item is subject to rule 5) |
110.80 |
| 65102 |
Compatibility tests by crossmatch — all tests performed on any 1 day in excess of 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105 (Item is subject to rule 5) |
167.50 |
| 65105 |
Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any 1 day for up to 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090 or 65096 (Item is subject to rule 5) |
110.80 |
| 65108 |
Compatibility testing using at least a 3 cell panel and issue of red cells for transfusion — all tests performed on any 1 day in excess of 6 units, including: (a) all grouping checks of the patient and donor; and (b) examination for antibodies and, if necessary, identification of any antibodies detected; and (c) (if performed) any tests described in item 65060, 65070, 65090, 65096, 65099 or 65105 (Item is subject to rule 5) |
167.50 |
| 65109 | Release of fresh frozen plasma or cryoprecipitate for the use in a patient for the correction of a coagulopathy — 1 release | 13.10 |
| 65110 | Release of compatible fresh platelets for the use in a patient for platelet support as prophylaxis to minimize bleeding or during active bleeding — 1 release | 13.10 |
| 65111 | Examination of serum for blood group antibodies (including identification and, if necessary, quantitation of any antibodies detected) | 23.60 |
[19] Schedule 1, Part 3, items 65129 to 65171
substitute
| 65129 | 4 or more tests described in item 65120 | 36.10 |
| 65137 | A test for the presence of lupus anticoagulant, not being a service connected with a service to which item 65175, 65176, 65177, 65178 or 65179 applies | 25.75 |
| 65142 | Confirmation or clarification of an abnormal or indeterminate result of a test mentioned in item 65175, by testing a specimen collected on a different day — 1 or more tests | 25.75 |
| 65144 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or other substances; or heparin, low molecular weight heparins, heparinoid or other drugs — 1 or more tests | 57.55 |
| 65147 | Quantitation of anti‑Xa activity when monitoring is required for a patient receiving a low molecular weight heparin or heparinoid — 1 test | 38.55 |
| 65150 |
Quantitation of von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor assay), von Willebrand factor collagen binding activity, factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, circulating coagulation factor inhibitors other than by Bethesda assay — 1 test (Item is subject to rule 6) |
72.15 |
| 65153 |
2 tests described in item 65150 (Item is subject to rule 6) |
144.35 |
| 65156 |
3 or more tests described in item 65150 (Item is subject to rule 6) |
216.50 |
| 65157 |
A test described in item 65150, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
72.15 |
| 65158 |
A test described in item 65150, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
72.15 |
| 65159 | Quantitation of circulating coagulation factor inhibitors by Bethesda assay — 1 test | 72.15 |
| 65162 | Examination of a maternal blood film for the presence of fetal red blood cells (Kleihauer test) | 10.55 |
| 65165 | Detection and quantitation of fetal red blood cells in the maternal circulation by detection of red cell antigens using flow cytometric methods including (if performed) any test described in item 65070 or 65162 | 35.05 |
| 65166 |
A test described in item 65165 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
35.05 |
| 65171 | A test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency or activated protein C resistance in a first degree relative of a person who has a proven deficiency mentioned in this item — 1 or more tests | 25.75 |
| 65175 |
A test for the presence of antithrombin III deficiency, protein C deficiency, protein S deficiency, lupus anticoagulant, activated protein C resistance, if the request for the test specifically identifies that the patient has a history of venous thromboembolism — quantitation by 1 or more techniques — 1 test (Item is subject to rule 6) |
25.75 |
| 65176 |
2 tests described in item 65175 (Item is subject to rule 6) |
49.45 |
| 65177 |
3 tests described in item 65175 (Item is subject to rule 6) |
73.20 |
| 65178 |
4 tests described in item 65175 (Item is subject to rule 6) |
96.85 |
| 65179 |
5 tests described in item 65175 (Item is subject to rule 6) |
120.55 |
| 65180 |
A test described in item 65175, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
25.75 |
| 65181 |
A test described in item 65175, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
23.70 |
[20] Schedule 1, Part 3, items 66551 and 66554
substitute
| 66551 |
Quantitation of glycosylated haemoglobin performed in the management of established diabetes (Item is subject to rule 25) |
17.10 |
| 66554 |
Quantitation of glycosylated haemoglobin performed in the management of pre‑existing diabetes where the patient is pregnant — including a service in item 66551 (if performed) (Item is subject to rule 25) |
17.10 |
[21] Schedule 1, Part 3, items 66605 to 66623
substitute
| 66605 |
Vitamins — quantitation of vitamins A, B1, B2, B3, B6, C and E in blood, urine or other body fluid (Item is subject to rule 25) |
31.15 |
| 66606 |
A test described in item 66605 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18, 18A and 25) |
31.15 |
| 66608 | Vitamin D or D fractions — 1 or more tests | 43.00 |
| 66609 |
A test described in item 66608 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
43.00 |
| 66623 |
All qualitative and quantitative tests on blood, urine or other body fluid for: (a) a drug or drugs of abuse (including illegal drugs and legally available drugs taken other than in appropriate dosage); or (b) ingested or absorbed toxic chemicals; including a service described in item 66800, 66803, 66806, 66812 or 66815 (if performed), but excluding: (c) the surveillance of sports people and athletes for performance improving substances; and (d) the monitoring of patients participating in a drug abuse treatment program |
42.25 |
[22] Schedule 1, Part 3, items 66638 to 66655
substitute
| 66638 | Isoelectric focussing or similar methods for determination of alpha‑1‑antitrypsin phenotype in serum — 1 or more tests | 29.70 |
| 66639 |
A test described in item 66638 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
29.70 |
| 66641 |
Electrophoresis of serum or other body fluid to demonstrate: (a) the isoenzymes of lactate dehydrogenase; or (b) the isoenzymes of alkaline phosphatase; including the preliminary quantitation of total relevant enzyme activity — 1 or more tests |
29.70 |
| 66642 |
A test described in item 66641 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
29.70 |
| 66644 | C‑1 esterase inhibitor — quantitation | 20.50 |
| 66647 | C‑1 esterase inhibitor — functional assay | 45.90 |
| 66650 |
Alpha‑fetoprotein, CA‑15.3 antigen (CA15.3), CA‑19.9 antigen (CA19.9), CA‑125 antigen (C125), cancer associated serum antigen (CASA), carcinoembryonic antigen (CEA), human chorionic gonadotrophin (HCG), mammary serum antigen (MSA), thyroglobulin in serum or other body fluid, in the monitoring of malignancy or in the detection or monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour — quantitation — 1 test (Item is subject to rule 6) |
24.75 |
| 66651 |
A test described in item 66650, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
24.75 |
| 66652 |
A test described in item 66650, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
20.65 |
| 66653 |
2 or more tests described in item 66650 (Item is subject to rule 6) |
45.40 |
| 66655 |
Prostate specific antigen — quantitation (Item is subject to rule 25) |
20.50 |
[23] Schedule 1, Part 3, items 66662 to 66667
substitute
| 66662 | Quantitation of hormone receptors on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast — 1 or more tests | 81.35 |
| 66663 |
A test described in item 66662 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
81.35 |
| 66665 | Lead quantitation in blood or urine (other than for occupational health screening purposes) to a maximum of 3 tests in a 6 month period — each test | 31.15 |
| 66666 |
A test described in item 66665 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
31.15 |
| 66667 | Quantitation of serum zinc in a patient receiving intravenous alimentation — each test | 31.15 |
[24] Schedule 1, Part 3, items 66669, 66670, 66672 and 66673
omit
[25] Schedule 1, Part 3, items 66686 to 66716
substitute
| 66686 |
Performance of 1 or more of the following procedures: (a) growth hormone suppression by glucose loading; (b) growth hormone stimulation by exercise; (c) dexamethasone suppression test; (d) sweat collection by iontophoresis for chloride analysis; (e) pharmacological stimulation of growth hormone |
51.55 |
| 66695 |
Quantitation in blood or urine of hormones and hormone binding proteins — ACTH, aldosterone, androstenedione, C‑peptide, calcitonin, cortisol, cyclic AMP, DHEAS, 11‑deoxycortisol, dihydrotestosterone, FSH, gastrin, glucagon, growth hormone, hydroxyprogesterone, insulin, LH, oestradiol, oestrone, progesterone, prolactin, PTH, renin, sex hormone binding globulin, somatomedin C(IGF –1), free or total testosterone, urine steroid fraction or fractions, vasoactive intestinal peptide, vasopressin (antidiuretic hormone) — 1 test (Item is subject to rule 6) |
30.70 |
| 66696 |
A test described in item 66695, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP (Item is subject to rules 6, 18 and 18A) |
30.70 |
| 66697 |
A test described in item 66695, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
13.30 |
| 66698 |
2 tests described in item 66695 (Item is subject to rule 6) |
44.00 |
| 66701 |
3 tests described in item 66695 (Item is subject to rule 6) |
57.30 |
| 66704 |
4 tests described in item 66695 (Item is subject to rule 6) |
70.60 |
| 66707 |
5 tests described in item 66695 (Item is subject to rule 6) |
83.90 |
| 66710 |
6 or more tests described in item 66695 (Item is subject to rule 6) |
97.45 |
| 66711 |
Quantitation in saliva of cortisol in: (a) the investigation of Cushing’s syndrome; or (b) the management of children with congenital adrenal hyperplasia; 1 test (Item is subject to rule 6) |
30.70 |
| 66712 |
Two tests described in item 66711 (Item is subject to rule 6) |
43.80 |
| 66714 |
A test described in item 66711, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP (Item is subject to rules 6, 18 and 18A) |
30.70 |
| 66715 |
A test described in item 66711, if rendered by a receiving APP, where 1 test in the item has been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
13.10 |
| 66716 | TSH quantitation | 25.45 |
[26] Schedule 1, Part 3, after item 66722
insert
| 66723 |
A test described in item 66722, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
38.55 |
| 66724 |
A test described in item 66722, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
13.40 |
[27] Schedule 1, Part 3, item 66737
omit
[28] Schedule 1, Part 3, items 66750 to 66758
substitute
| 66750 |
Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality: (a) total human chorionic gonadotrophin (total HCG); (b) free alpha human chorionic gonadotrophin (free alpha HCG); (c) free beta human chorionic gonadotrophin (free beta HCG); (d) pregnancy associated plasma protein A (PAPP‑A); |
40.45 | |
|
(e) unconjugated oestriol (uE3); (f) alpha‑fetoprotein (AFP); including (if performed) a service described in item 73527 or 73529 (Item is subject to rule 25) |
|||
| 66751 |
Quantitation, in pregnancy, of any 3 or more tests described in item 66750 (Item is subject to rule 25) |
56.20 | |
| 66752 | Quantitation of citrate, oxalate, total free fatty acids, cysteine, homocysteine, cystine or other amino acids and hydroxyproline (except if performed as part of item 66773 or 66776) — 1 test | 25.10 | |
| 66755 | 2 or more tests described in item 66752 | 39.50 | |
| 66756 | Quantitation of 10 or more amino acids for the diagnosis of inborn errors of metabolism — up to 4 tests in a 12 month period on specimens of plasma, CSF and urine | 100.00 | |
| 66757 | Quantitation of 10 or more amino acids for monitoring of previously diagnosed inborn errors of metabolism in 1 tissue type | 100.00 | |
| 66758 | Quantitation of angiotensin converting enzyme, or cholinesterase — 1 or more tests | 25.10 | |
[29] Schedule 1, Part 3, items 66779 to 66818
substitute
| 66779 | Adrenaline, noradrenaline, dopamine, histamine, hydroxyindoleacetic acid (5HIAA), hydroxymethoxymandelic acid (HMMA), homovanillic acid (HVA), metanephrines, methoxyhydroxyphenylethylene glycol (MHPG), phenylacetic acid (PAA) or serotonin — quantitation — 1 or more tests | 40.65 |
| 66780 |
A test described in item 66779 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
40.65 |
| 66782 | Porphyrins or porphyrins precursors — detection in plasma, red cells, urine or faeces — 1 or more tests | 13.40 |
| 66783 |
A test described in item 66782 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
13.40 |
| 66785 |
Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 1 test (Item is subject to rule 6) |
40.65 |
| 66788 |
Porphyrins or porphyrins precursors — quantitation in plasma, red cells, urine or faeces — 2 or more tests (Item is subject to rule 6) |
67.00 |
| 66789 |
A test described in item 66785 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
40.65 |
| 66790 |
A test described in item 66785, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
26.35 |
| 66791 | Porphyrin biosynthetic enzymes — measurement of activity in blood cells or other tissues — 1 or more tests | 75.75 |
| 66792 |
A test described in item 66791 if rendered by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
75.75 |
| 66800 |
Quantitation in blood, urine or other body fluid by any method (except reagent tablet or reagent strip) of any of the following used therapeutically by the patient from whom the specimen was taken: amikacin, carbamazepine, digoxin, disopyramide, ethanol, ethosuximide, gentamicin, lignocaine, lithium, netilmicin, paracetamol, phenobarbitone, phenytoin, primidone, procainamide, quinidine, salicylate, theophylline, tobramycin, valproate or vancomycin — 1 test (Item is subject to rule 6) |
18.45 |
| 66803 |
2 tests described in item 66800 (Item is subject to rule 6) |
31.05 |
| 66804 |
A test described in item 66800 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
18.45 |
| 66805 |
A test described in item 66800, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
12.60 |
| 66806 |
3 tests described in item 66800 (Item is subject to rule 6) |
43.65 |
| 66812 |
Quantitation, not elsewhere described in this table by any method or methods, in blood, urine or other body fluid, of a drug being used therapeutically by the patient from whom the specimen was taken — 1 test (Item is subject to rule 6) |
35.45 |
| 66815 |
2 tests described in item 66812 (Item is subject to rule 6) |
60.60 |
| 66816 |
A test described in item 66812 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
35.45 |
| 66817 |
A test described in item 66812, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18 and 18A) |
25.15 |
| 66819 |
Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue — 1 test (Item is subject to rules 6, 22 and 25) |
31.15 |
| 66820 |
A test described in item 66819 if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18, 18A, 22 and 25) |
31.15 |
| 66821 |
A test described in item 66819, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18, 18A, 22 and 25) |
22.20 |
| 66822 |
Quantitation of copper, manganese, selenium or zinc (except if item 66667 applies), in blood, urine or other body fluid or tissue — 2 or more tests (Item is subject to rules 6, 22 and 25) |
53.35 |
| 66825 |
Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue — 1 test (Item is subject to rules 6, 22 and 25) |
31.15 |
| 66826 |
A test described in item 66825 if rendered by a receiving APP where no tests have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18, 18A, 22 and 25 ) |
31.15 |
| 66827 |
A test described in item 66825, if rendered by a receiving APP, where 1 or more tests in the item have been rendered by the referring APP — 1 test (Item is subject to rules 6, 18, 18A, 22 and 25) |
22.20 |
| 66828 |
Quantitation of aluminium (except if item 66671 applies), arsenic, beryllium, cadmium, chromium, gold, mercury, nickel or strontium, in blood, urine or other body fluid or tissue — 2 or more tests (Item is subject to rules 6, 22 and 25) |
53.35 |
[30] Schedule 1, Part 3, items 69312 to 69333
substitute
| 69312 |
Microscopy and culture to detect pathogenic micro‑organisms from urethra, vagina, cervix or rectum (except for faecal pathogens), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in items 69300, 69303, 69306 and 69318; 1 or more tests on 1 or more specimens |
34.00 |
| 69316 |
Detection of Chlamydia trachomatis by any method — 1 test (Item is subject to rule 26) |
28.85 |
| 69317 |
This item applies if: (a) 1 test described in item 69316 is performed; and (b) 1 test described in item 69494 is performed (Item is subject to rule 26) |
36.10 |
| 69318 |
Microscopy and culture to detect pathogenic micro‑organisms from specimens of sputum (except when part of items 69324, 69327 and 69330), including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or |
34.00 |
|
(b) a service described in items 69300, 69303, 69306 and 69312; 1 or more tests on 1 or more specimens |
||
| 69319 |
This item applies if: (a) 1 test described in item 69316 is performed; and (b) 2 tests described in item 69494 are performed (Item is subject to rule 26) |
43.25 |
| 69321 |
Microscopy and culture of post‑operative wounds, aspirates of body cavities, synovial fluid, CSF or operative or biopsy specimens, for the presence of pathogenic micro‑organisms involving aerobic and anaerobic cultures and the use of different culture media, and including (if performed): (a) pathogen identification and antibiotic susceptibility testing; or (b) a service described in item 69300, 69303, 69306, 69312 or 69318; specimens from 1 or more sites |
48.45 |
| 69324 |
Microscopy (with appropriate stains) and culture for mycobacteria — 1 specimen of sputum, urine or other body fluid or 1 operative or biopsy specimen, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service mentioned in item 69300 |
43.30 |
| 69325 |
A service described in item 69324 if the microscopy and culture is performed by a receiving APP (Item is subject to rules 18 and 18A) |
43.30 |
| 69327 |
Microscopy (with appropriate stains) and culture for mycobacteria — 2 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service described in item 69300 |
85.55 |
| 69328 |
A service described in item 69327 if the microscopy and culture is performed by a receiving APP (Item is subject to rules 18 and 18A) |
85.55 |
| 69330 |
Microscopy (with appropriate stains) and culture for mycobacteria — 3 specimens of sputum, urine or other body fluids or operative or biopsy specimens, including (if performed): (a) microscopy and culture of other bacterial pathogens isolated as a result of this procedure; or (b) pathogen identification and antibiotic susceptibility testing; including a service described in item 69300 |
128.85 |
| 69331 |
A service described in item 69330 if the microscopy and culture is performed by a receiving APP (Item is subject to rules 18 and 18A) |
128.85 |
| 69333 |
Urine examination (including serial examination) by any means other than simple culture by dip slide, including: (a) cell count; and (b) culture; and (c) colony count; and (d) (if performed) stained preparations; and (e) (if performed) identification of cultured pathogens; and |
20.70 |
|
(f) (if performed) antibiotic suseptibility testing; and (g) (if performed) examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts |
[31] Schedule 1, Part 3, items 69363, 69364, 69365 and 69367
substitute
| 69363 | Detection of Clostridium difficile or Clostridium difficile toxin (except if a service described in item 69345 has been performed) — 1 or more tests | 28.85 |
[32] Schedule 1, Part 3, after item 69378
insert
| 69379 |
A test described in item 69378 if the quantitation is performed by a receiving APP — 1 or more tests on 1 or more specimens (Item is subject to rules 18 and 18A) |
181.45 |
[33] Schedule 1, Part 3, items 69382 to 69402
substitute
| 69382 | Quantitation of HIV viral RNA load in cerebrospinal fluid in a HIV sero‑positive patient — 1 or more tests on 1 or more specimens | 181.45 |
| 69383 |
A test described in item 69381 if the quantitation is performed by a receiving APP — 1 or more tests on 1 or more specimens (Item is subject to rules 18 and 18A) |
181.45 |
| 69384 |
Quantitation of 1 antibody to microbial or exogenous antigens not elsewhere described in this table — 1 test (Item is subject to rule 6) |
15.75 |
| 69387 |
2 tests described in item 69384 (Item is subject to rule 6) |
29.75 |
| 69390 |
3 tests described in item 69384 (Item is subject to rule 6) |
43.75 |
| 69393 |
4 tests described in item 69384 (Item is subject to rule 6) |
57.75 |
| 69396 |
5 tests described in item 69384 (Item is subject to rule 6) |
71.75 |
| 69399 |
6 or more tests described in item 69384 (Item is subject to rule 6) |
85.75 |
| 69400 |
This item applies to a test described in item 69384 if: (a) a referring APP has not performed a test described in item 69384; and (b) a receiving APP performs a test described in item 69384; 1 test (Item is subject to rules 6, 18 and 18A) |
15.75 |
| 69401 |
A test described in item 69384 if a referring APP has performed a test or tests described in item 69384 — 1 test (Item is subject to rules 6, 18 and 18A) |
14.00 |
[34] Schedule 1, Part 3, items 69415 to 69471
substitute
| 69415 |
Microbiological serology during a pregnancy (except in the investigation of a clinically apparent intercurrent microbial illness or close contact with a patient suffering from parvovirus infection or varicella during that pregnancy) including: (a) the determination of all of the following — rubella immune status, specific syphilis serology, carriage of hepatitis B, hepatitis C antibody, HIV antibody; and (b) (if performed) a service described in 1 or more of items 69384, 69475, 69478 and 69481 |
61.95 |
| 69418 |
A test for high risk human papillomaviruses (HPV) in a patient who: (a) within the 2 year period before the test, has received excisional or ablative treatment for high grade squamous intraepithelial lesions (HSIL) of the cervix; or |
64.00 |
| (b) within the 2 year period before the test, has had a positive HPV test after excisional or ablative treatment for HSIL of the cervix; or | ||
|
(c) is undergoing annual cytological review following treatment for HSIL of the cervix; 1 test (Item is subject to rule 25) |
||
| 69419 |
A test described in item 69418 if the test is performed by a receiving APP — 1 test (Item is subject to rules 18, 18A and 25) |
64.00 |
| 69445 |
Detection of hepatitis C viral RNA in a patient undertaking antiviral therapy for chronic HCV hepatitis (including a service described in item 69499) — 1 test (Item is subject to rule 25) |
92.80 |
| 69451 |
A test described in item 69445 if the test is performed by a receiving APP — 1 test (Item is subject to rules 18, 18A and 25) |
92.80 |
| 69471 | Test of cell‑mediated immunity in blood for the detection of active tuberculosis or atypical mycobacterial infection in an immunosuppressed or immunocompromised patient — 1 test | 35.15 |
[35] Schedule 1, Part 3, items 69484 and 69486
substitute
| 69484 | Supplementary test for hepatitis B surface antigen or hepatitis C antibody using a different assay on a specimen that yielded a reactive result on initial testing | 17.20 |
| 69488 |
Quantitation of HCV RNA load in plasma or serum in: (a) the pre‑treatment evaluation, of a patient with chronic HCV hepatitis, for antiviral therapy; or (b) the assessment of efficacy of antiviral therapy for such a patient; if the test is requested by, or on the advice of, the specialist or consultant physician who manages the treatment of the patient (including a service described in item 69445 or 69499) (Item is subject to rule 25) |
181.45 |
| 69489 |
A test described in item 69488 if the test is performed by a receiving APP (Item is subject to rules 18, 18A and 25) |
181.45 |
| 69491 |
Nucleic acid amplification and determination of hepatitis C virus (HCV) genotype if: (a) the patient is HCV RNA positive and is being evaluated for antiviral therapy of chronic HCV hepatitis; and |
206.20 |
|
(b) the request for the test is made by, or on the advice of, the specialist or consultant physician managing the treatment of the patient (Item is subject to rule 25) |
||
| 69492 |
A service described in item 69491 if the test is performed by a receiving APP (Item is subject to rules 18, 18A and 25) |
206.20 |
| 69494 |
Detection of a virus, microbial antigen or microbial nucleic acid (not elsewhere described in this table) — 1 test (Item is subject to rules 6 and 26) |
28.85 |
| 69495 |
2 tests described in item 69494 (Item is subject to rules 6 and 26) |
36.10 |
| 69496 |
3 or more tests described in item 69494 (Item is subject to rules 6 and 26) |
43.35 |
| 69497 |
This item applies to a test described in item 69494 if: (a) a referring APP has not performed the test described in item 69494; and (b) a receiving APP performs the test described in item 69494; 1 test (Item is subject to rules 6, 18, 18A and 26) |
28.85 |
| 69498 |
This item applies to a test described in item 69494 if: (a) a referring APP has performed the test or tests described in item 69494; and (b) a receiving APP has performed the test or tests described in item 69494; 1 test (Item is subject to rules 6, 18, 18A and 26) |
7.25 |
| 69499 |
Detection of hepatitis C viral RNA if at least 1 of the following criteria is satisfied: (a) the patient is hepatitis C sero‑positive; (b) the patient’s serological status is uncertain after testing; (c) the test is performed for the purpose of: (i) determining the hepatitis C status of an immunosuppressed or immunocompromised patient; or |
92.80 |
|
(ii) the detection of acute hepatitis C prior to seroconversion where considered necessary for the clinical management of the patient (Item is subject to rules 19 and 25) |
||
| 69500 |
A test described in item 69499 if the test is performed by a receiving APP (Item is subject to rules 18, 18A, 19 and 25) |
92.80 |
[36] Schedule 1, Part 3, after item 71075
insert
| 71076 |
A test described in item 71073 if the test is performed by a receiving APP — 1 test (Item is subject to rules 18 and 18A) |
108.00 |
[37] Schedule 1, Part 3, items 71089 to 71097
substitute
| 71089 |
Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this table — 1 test (Item is subject to rule 6) |
29.65 |
| 71090 |
This item applies to a test described in item 71089 if: (a) a referring APP has not performed the test described in item 71089; and (b) a receiving APP performs the test described in item 71089; 1 test (Item is subject to rules 6, 18 and 18A) |
29.65 |
| 71091 |
2 tests described in item 71089 (Item is subject to rule 6) |
53.75 |
| 71092 |
This item applies to a test described in item 71089 if: (a) a referring APP has performed the test or tests described in item 71089; and (b) a receiving APP performs the test or tests described in item 71089; 1 test (Item is subject to rules 6, 18 and 18A) |
24.10 |
| 71093 |
3 or more tests described in item 71089 (Item is subject to rule 6) |
77.75 |
| 71095 | Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years | 41.25 |
| 71096 |
A test described in item 71095 if the quantitation is performed by a receiving APP (Item is subject to rules 18 and 18A) |
41.25 |
| 71097 | Antinuclear antibodies — detection in serum or other body fluids, including quantitation if required | 24.85 |
[38] Schedule 1, Part 3, items 71109, 71113, 71115 and 71117
omit
[39] Schedule 1, Part 3, items 71147 to 71164
substitute
| 71147 |
HLA‑B27 typing (Item is subject to rule 27) |
41.25 |
| 71148 |
A test described in item 71147 if a receiving APP performs the test (Item is subject to rules 18, 18A and 27) |
41.25 |
| 71149 | Complete tissue typing for 4 HLA‑A and HLA‑B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147 | 110.15 |
| 71151 | Tissue typing for HLA‑DR, HLA‑DP and HLA‑DQ Class II antigens (including any separation of leucocytes) — phenotyping or genotyping of 2 or more antigens | 120.95 |
| 71153 |
Testing, for assessment or diagnosis of systemic inflammatory disease or vasculitis, for the presence of an antibody by 1 of the following tests: (a) antineutrophil cytoplasmic antibody (ANCA) immunofluorescence test; (b) antineutrophil proteinase 3 antibody (PR3 ANCA) test; (c) antimyeloperoxidase antibody (MPO ANCA) test; (d) antiglomerular basement membrane antibody (GBM ANCA) test (Item is subject to rules 6 and 23) |
35.15 |
| 71154 |
This item applies to a test described in item 71153 if: (a) a referring APP has performed a test or tests described in item 71153; and (b) a receiving APP performs the test described in item 71153; 1 test (Item is subject to rules 6, 18, 18A and 23) |
35.15 |
| 71155 |
Testing for the presence of 2 antibodies by tests mentioned in item 71153 (Item is subject to rules 6 and 23) |
48.25 |
| 71156 |
This item applies to a test described in item 71153 (other than a test described in item 71154) if: (a) a referring APP has performed the test or tests described in item 71153; and (b) a receiving APP performs the test or tests described in item 71153; 1 test (Item is subject to rules 6, 18, 18A and 23) |
13.10 |
| 71157 |
Testing for the presence of 3 antibodies by tests mentioned in item 71153 (Item is subject to rules 6 and 23) |
61.35 |
| 71159 |
Testing for the presence of 4 antibodies by tests mentioned in item 71153 (Item is subject to rules 6 and 23) |
74.45 |
| 71163 |
Detection of 1 of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes, including a service described in item 71066 (if performed): (a) antibodies to gliadin; (b) antibodies to endomysium; (c) antibodies to tissue transglutaminase; 1 test |
25.15 |
| 71164 | 2 or more tests mentioned in item 71163, including a service described in item 71066 (if performed) | 40.60 |
| 71165 |
Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, cardiolipin, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) — detection, including quantitation if required, of 1 antibody (Item is subject to rule 6) |
35.15 |
| 71166 |
Detection of 2 antibodies described in item 71165 (Item is subject to rule 6) |
48.25 |
| 71167 |
Detection of 3 antibodies described in item 71165 (Item is subject to rule 6) |
61.35 |
| 71168 |
Detection of 4 or more antibodies described in item 71165 (Item is subject to rule 6) |
74.45 |
| 71169 |
This item applies to a service described in item 71165 if: (a) a referring APP has not performed the service described in item 71165; and (b) a receiving APP performs the service described in item 71165 (Item is subject to rules 6, 18 and 18A) |
35.15 |
| 71170 |
This item applies to a service described in item 71165 if: (a) a referring APP has performed the test or tests described in item 71165; and (b) a receiving APP performs the test or tests described in item 71165; 1 test (Item is subject to rules 6, 18 and 18A) |
13.10 |
[40] Schedule 1, Part 3, items 73308 to 73320
substitute
| 73308 | Characterisation of the genotype of a patient for Factor V Leiden gene mutation, or detection of other relevant mutations in the investigation of proven venous thrombosis or pulmonary embolism — 1 or more tests | 37.10 |
| 73309 |
A test described in item 73308 if the test is performed by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
37.10 |
| 73311 | Characterisation of the genotype of a person who is a first degree relative of a person who has been proven to have 1 or more abnormal genotypes under item 73308 — 1 or more tests | 37.10 |
| 73312 |
A test described in item 73311 if the test is performed by a receiving APP — 1 or more tests (Item is subject to rules 18 and 18A) |
37.10 |
| 73314 |
Characterisation of gene rearrangement by nucleic acid amplification in the diagnosis and monitoring of patients with laboratory evidence of: (a) acute myeloid leukaemia; or (b) acute promyelocytic leukaemia; or (c) acute lymphoid leukaemia; or (d) chronic myeloid leukaemia (Item is subject to rule 25) |
235.00 |
| 73315 |
A service described in item 73314 if the characterisation is performed by a receiving APP — 1 or more tests (Item is subject to rules 18, 18A and 25) |
235.00 |
| 73317 |
Detection of the C282Y genetic mutation of the HFE gene and, if performed, detection of other mutations for haemochromatosis where: (a) the patient has an elevated transferrin saturation or elevated serum ferritin on testing of repeated specimens; or (b) the patient has a first degree relative with haemochromatosis; or (c) the patient has a first degree relative with homozygosity for the C282Y genetic mutation, or with compound heterozygosity for recognised genetic mutations for haemochromatosis (Item is subject to rule 20) |
37.10 |
| 73318 |
A test described in item 73317 if the detection is performed by a receiving APP — 1 or more tests (Item is subject to rules 18, 18A and 20) |
37.10 |
| 73320 |
Detection of HLA‑B27 by nucleic acid amplification including a service described in item 71147 unless the service in this item is rendered as a pathologist‑determinable service (Item is subject to rule 27) |
41.25 |
| 73321 |
A test described in item 73320 if the detection is performed by a receiving APP — 1 or more tests (Item is subject to rules 18, 18A and 27) |
41.25 |
[41] Schedule 1, Part 3, Group P10
substitute
|
Group P10 — Patient episode initiation Note Items 73922 to 73927 in Subgroup 1 apply to the initiation of a patient episode consisting of a service described in a particular item in the table. If the initiation of the patient episode consists of a service described in an item other than those particular services, an item mentioned in Subgroup 2 will apply to the patient episode. |
||
|
Subgroup 1 — Initiation of a patient episode involving particular services |
||
| 73922 |
Initiation of a patient episode that consists of a service described in item 73053, 73055 or 73057 (in circumstances other than those described in item 73923) (Item is subject to rule 14) |
8.25 |
| 73923 |
Initiation of a patient episode that consists of a service described in item 73053, 73055 or 73057 if: (a) the person is a private patient in a recognised hospital; or (b) the person receives the service from a prescribed laboratory (Item is subject to rule 14) |
2.40 |
| 73924 |
Initiation of a patient episode that consists of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 (in circumstances other than those described in item 73925) from a person who is an in‑patient of a hospital (Item is subject to rule 14) |
14.75 |
| 73925 |
Initiation of a patient episode that consists of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 if the person is: (a) a private patient of a recognised hospital; or (b) a private patient of a hospital who receives the service or services from a prescribed laboratory (Item is subject to rule 14) |
2.40 |
| 73926 |
Initiation of a patient episode that consists only of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 (in circumstances other than those described in item 73927) from a person who not is a patient of a hospital (Item is subject to rule 14) |
8.25 |
| 73927 |
Initiation of a patient episode by a prescribed laboratory that consists of 1 or more services described in items 72813, 72816, 72817, 72818, 72823, 72824, 72825, 72826, 72830 and 72836 from a person who is not a patient of a hospital (Item is subject to rule 14) |
2.40 |
|
Subgroup 2 — Initiation of a patient episode involving other services |
||
| 73928 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73929) if the specimen is collected in an approved collection centre (Item is subject to rule 14) |
17.40 |
| 73929 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected in an approved collection centre by: (a) an approved pathology practitioner of a prescribed laboratory; or (b) an employee of an approved pathology authority of a prescribed laboratory (Item is subject to rule 14) |
2.40 |
| 73930 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73931) if the specimen is collected from a person who is an in‑patient of a hospital other than a recognised hospital by an approved pathology practitioner or an employee of an approved pathology authority (Item is subject to rule 14) |
17.70 |
| 73931 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected: (a) from a person who is a private patient of a hospital by an approved pathology practitioner of a prescribed laboratory; or (b) from a person who is a private patient of a hospital by an employee of an approved pathology authority that operates a prescribed laboratory; or (c) from a person who is a private patient of a recognised hospital by an approved pathology practitioner of an approved pathology authority; or (d) from a person who is a private patient of a recognised hospital by an employee of an approved pathology authority (Item is subject to rule 14) |
2.40 |
| 73932 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73933) if the specimen is collected from a person in the place where the person resides, and that place is not an institution, by: (a) an approved pathology practitioner of an approved pathology authority; or (b) an employee of an approved pathology authority (Item is subject to rule 14) |
10.30 |
| 73933 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from a person in the place where the person resides, and that place is not an institution, by: (a) an approved pathology practitioner of a prescribed laboratory; or (b) an employee of an approved pathology authority that operates a prescribed laboratory (Item is subject to rule 14) |
2.40 |
| 73934 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73935) if the specimen is collected from a person in an institution by: (a) an approved pathology practitioner; or (b) an employee of an approved pathology authority (Item is subject to rule 14) |
17.70 |
| 73935 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from a person in an institution by: (a) an approved pathology practitioner of a prescribed laboratory; or (b) an employee of an approved pathology authority that operates a prescribed laboratory (Item is subject to rule 14) |
2.40 |
| 73936 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926, 73927 or 73937) if the specimen is collected from the person by the person (Item is subject to rule 14) |
9.80 |
| 73937 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected from the person by the person, and: (a) the service is performed in a prescribed laboratory; or (b) the person is a private patient in a recognised hospital (Item is subject to rule 14) |
2.40 |
| 73938 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in items 73922, 73923, 73924, 73925, 73926, 73927 or 73939) if the specimen is collected by, or on behalf of, the treating practitioner (Item is subject to rule 14) |
9.80 |
| 73939 |
Initiation of a patient episode by collection of a specimen for 1 or more services (in circumstances other than those described in item 73922, 73923, 73924, 73925, 73926 or 73927) if the specimen is collected by, or on behalf of, the treating practitioner and: (a) the service is performed in a prescribed laboratory; or (b) the person is a private patient in a recognised hospital (Item is subject to rule 14) |
2.40 |
[42] Schedule 1, Part 3, item 73921
substitute
| 73940 |
Receipt of a specimen by an approved pathology practitioner of an approved pathology authority from another approved pathology practitioner of another approved pathology authority (Item is subject to rules 14, 15 and 16) |
10.30 |
[43] Schedule 1, Part 4
omit
| Acetylcholine receptor — tissue antigens — antibodies | ARA | 71109 |
insert
| Acetylcholine receptor — tissue antigens — antibodies | ARA | 71165 |
[44] Schedule 1, Part 4
omit
| Activated Protein C resistance | APC | 65132–36, 65142, 65171 |
insert
| Activated Protein C resistance | APC | 65142, 65171, 65175–79 |
[45] Schedule 1, Part 4
omit
| Adrenal cortex — tissue antigens — antibodies | ADR | 71109 |
insert
| Adrenal cortex — tissue antigens — antibodies | ADR | 71165 |
[46] Schedule 1, Part 4
omit
| Aluminium | AL | 66672–73 |
insert
| Aluminium | AL | 66825, 66828 |
[47] Schedule 1, Part 4
omit
| Antibodies to tissue antigens — acetylcholine receptor | ARA | 71109 |
| Antibodies to tissue antigens — adrenal cortex | ADR | 71109 |
insert
| Antibodies to tissue antigens — acetylcholine receptor | ARA | 71165 |
| Antibodies to tissue antigens — adrenal cortex | ADR | 71165 |
[48] Schedule 1, Part 4
omit
| Antibodies to tissue antigens — cardiolipin | ACL | 71109 |
insert
| Antibodies to tissue antigens — cardiolipin | ACL | 71165 |
[49] Schedule 1, Part 4
omit
| Antibodies to tissue antigens — heart | AHE | 71109 |
| Antibodies to tissue antigens — histone | AHI | 71109 |
| Antibodies to tissue antigens — insulin receptor antibodies | INSA | 71109 |
| Antibodies to tissue antigens — intercellular cement substance of skin | ICCS | 71109 |
| Antibodies to tissue antigens — intrinsic factor | AIF | 71109 |
| Antibodies to tissue antigens — islet cell | AIC | 71109 |
insert
| Antibodies to tissue antigens — heart | AHE | 71165 |
| Antibodies to tissue antigens — histone | AHI | 71165 |
| Antibodies to tissue antigens — insulin receptor antibodies | INSA | 71165 |
| Antibodies to tissue antigens — intercellular cement substance of skin | ICCS | 71165 |
| Antibodies to tissue antigens — intrinsic factor | AIF | 71165 |
| Antibodies to tissue antigens — islet cell | AIC | 71165 |
[50] Schedule 1, Part 4
omit
| Antibodies to tissue antigens — lymphocyte | ALY | 71109 |
| Antibodies to tissue antigens — mitochondria | MA | 71119 |
| Antibodies to tissue antigens — neuron | ANE | 71109 |
| Antibodies to tissue antigens — neutrophil cytoplasm | ANCA | 71153 |
| Antibodies to tissue antigens — ovary | AOV | 71109 |
| Antibodies to tissue antigens — parathyroid | PTHA | 71109 |
| Antibodies to tissue antigens — platelet | APA | 71109 |
| Antibodies to tissue antigens — PM‑Sc1 | PM1 | 71119 |
| Antibodies to tissue antigens — reticulin | RCA | 71119 |
| Antibodies to tissue antigens — salivary gland | ASG | 71109 |
| Antibodies to tissue antigens — Scl‑70 | SCL | 71119 |
| Antibodies to tissue antigens — skeletal muscle | SLA | 71109 |
| Antibodies to tissue antigens — skin basement membrane | SKA | 71109 |
| Antibodies to tissue antigens — smooth muscle | SMA | 71119 |
| Antibodies to tissue antigens — thyroglobulin | ATG | 71109 |
| Antibodies to tissue antigens — thyroid microsome | TMA | 71109 |
| Antibodies to tissue antigens — tissue transglutaminase | TTG | 71163 |
| Antibodies to tissue antigens — TSH receptor antibody test | TSHA | 71109 |
insert
| Antibodies to tissue antigens — lymphocyte | ALY | 71165 |
| Antibodies to tissue antigens — mitochondria | MA | 71119 |
| Antibodies to tissue antigens — neuron | ANE | 71165 |
| Antibodies to tissue antigens — neutrophil cytoplasm | ANCA | 71153 |
| Antibodies to tissue antigens — ovary | AOV | 71165 |
| Antibodies to tissue antigens — parathyroid | PTHA | 71165 |
| Antibodies to tissue antigens — platelet | APA | 71165 |
| Antibodies to tissue antigens — PM‑Sc1 | PM1 | 71119 |
| Antibodies to tissue antigens — reticulin | RCA | 71119 |
| Antibodies to tissue antigens — salivary gland | ASG | 71165 |
| Antibodies to tissue antigens — Scl‑70 | SCL | 71119 |
| Antibodies to tissue antigens — skeletal muscle | SLA | 71165 |
| Antibodies to tissue antigens — skin basement membrane | SKA | 71165 |
| Antibodies to tissue antigens — smooth muscle | SMA | 71119 |
| Antibodies to tissue antigens — thyroglobulin | ATG | 71165 |
| Antibodies to tissue antigens — thyroid microsome | TMA | 71165 |
| Antibodies to tissue antigens — tissue transglutaminase | TTG | 71163 |
| Antibodies to tissue antigens — TSH receptor antibody test | TSHA | 71165 |
[51] Schedule 1, Part 4
omit
| Antithrombin III | ATH | 65132–36, 65142, 65171 |
insert
| Antithrombin III | ATH | 65142, 65171, 65175–79 |
[52] Schedule 1, Part 4
omit
| Arsenic | AS | 66672–73 |
insert
| Arsenic | AS | 66825, 66828 |
[53] Schedule 1, Part 4
omit
| Beryllium | BE | 66672–73 |
insert
| Beryllium | BE | 66825, 66828 |
[54] Schedule 1, Part 4
omit
| Cadmium | CD | 66672–73 |
insert
| Cadmium | CD | 66825, 66828 |
[55] Schedule 1, Part 4
omit
| Cardiolipin — tissue antigens — antibodies | ACL | 71109 |
insert
| Cardiolipin — tissue antigens — antibodies | ACL | 71165 |
[56] Schedule 1, Part 4
omit
| Chlamydia — investigation by any method | CHLM | 69364 |
| Chlamydia — investigation by any method and N gonorrhoea by NAA methods | CHGO | 69364 |
| Chlamydia — microbial antibody testing | CHL | 69384 |
| Chlamydia — microbial antigen testing | MCCH | 69364 |
insert
| Chlamydia — investigation by any method | CHLM | 69494 |
| Chlamydia — investigation by any method and N gonorrhoea by NAA methods | CHGO | 69494 |
| Chlamydia — microbial antibody testing | CHL | 69384 |
| Chlamydia — microbial antigen testing | MCCH | 69494 |
[57] Schedule 1, Part 4
omit
| Chromium | CR | 66672–73 |
insert
| Chromium | CR | 66825, 66828 |
[58] Schedule 1, Part 4
omit
| Copper | CU | 66669–70 |
insert
| Copper | CU | 66819, 66822 |
[59] Schedule 1, Part 4
omit
| Cryptococcal antigen — microbial antigen testing | CRYN | 69364 |
| Cryptococcus — microbial antibody testing | CRY | 69384 |
| CSF — microscopy and culture of material from | MCPO | 69321 |
| CSF antigens — group B streptococcus | STB | 69364 |
| CSF antigens — Haemophilus influenzae | HI | 69364 |
| CSF antigens — Neisseria meningitidis | NMG | 69364 |
| CSF antigens — Streptococcus pneumoniae | SPN | 69364 |
insert
| Cryptococcal antigen — microbial antigen testing | CRYN | 69494 |
| Cryptococcus — microbial antibody testing | CRY | 69384 |
| CSF — microscopy and culture of material from | MCPO | 69321 |
| CSF antigens — group B streptococcus | STB | 69494 |
| CSF antigens — Haemophilus influenzae | HI | 69494 |
| CSF antigens — Neisseria meningitidis | NMG | 69494 |
| CSF antigens — Streptococcus pneumoniae | SPN | 69494 |
[60] Schedule 1, Part 4
omit
| Faecal antigen test for Helicobacter pylori | FAHP | 69364 |
insert
| Faecal antigen test for Helicobacter pylori | FAHP | 69494 |
[61] Schedule 1, Part 4
omit
| Glomerular basement membrane — tissue antigens — antibodies | GBA | 71109 |
insert
| Glomerular basement membrane — tissue antigens — antibodies | GBA | 71165 |
[62] Schedule 1, Part 4
omit
| Gold | AU | 66672–73 |
| Group B streptococcus — CSF antigens | STB | 69364 |
| Group B streptococcus — microbial antigen testing | STB | 69364 |
insert
| Gold | AU | 66825, 66828 |
| Group B streptococcus — CSF antigens | STB | 69494 |
| Group B streptococcus — microbial antigen testing | STB | 69494 |
[63] Schedule 1, Part 4
omit
| Haemophilus influenzae — CSF antigens | HI | 69364 |
| Haemophilus influenzae — microbial antibody testing | HUS | 69384 |
| Haemophilus influenzae — microbial antigen testing | HI | 69364 |
insert
| Haemophilus influenzae — CSF antigens | HI | 69494 |
| Haemophilus influenzae — microbial antibody testing | HUS | 69384 |
| Haemophilus influenzae — microbial antigen testing | HI | 69494 |
[64] Schedule 1, Part 4
omit
| Heart — tissue antigens — antibodies | AHE | 71109 |
insert
| Heart — tissue antigens — antibodies | AHE | 71165 |
[65] Schedule 1, Part 4
omit
| Hepatitis C — detection | RNAC | 69444 |
| Hepatitis C — genotype | GHCV | 69443 |
| Hepatitis C — quantitation | THCV | 69442 |
insert
| Hepatitis C — detection | RNAC | 69499 |
| Hepatitis C — genotype | GHCV | 69491 |
| Hepatitis C — quantitation | THCV | 69488 |
[66] Schedule 1, Part 4
omit
| Herpes simplex virus — direct detection from clinical material | HSV | 69364 |
| Herpes simplex virus — investigation by culture | HSVC | 69364 |
| Herpes simplex virus — microbial antibody testing | HPA | 69384 |
| Herpes simplex virus — microbial antigen testing | HSV | 69364 |
insert
| Herpes simplex virus — direct detection from clinical material | HSV | 69494 |
| Herpes simplex virus — investigation by culture | HSVC | 69494 |
| Herpes simplex virus — microbial antibody testing | HPA | 69384 |
| Herpes simplex virus — microbial antigen testing | HSV | 69494 |
[67] Schedule 1, Part 4
omit
| Histone — tissue antigens — antibodies | AHI | 71109 |
insert
| Histone — tissue antigens — antibodies | AHI | 71165 |
[68] Schedule 1, Part 4
omit
| Human papillomaviruses | HPV | 69486 |
insert
| Human papillomaviruses | HPV | 69418 |
[69] Schedule 1, Part 4
omit
| Insulin — tissue antigens — antibodies | AINS | 71109 |
| Insulin receptor antibodies — tissue antigens — antibodies | INSA | 71109 |
| Intercellular cement substance of skin — tissue antigens — antibodies | ICCS | 71109 |
| Intestinal disaccharidases | INTD | 66680 |
| Intrinsic factor — tissue antigens — antibodies | AIF | 71109 |
| Iron studies (iron, transferrin and ferritin) | IS | 66596 |
| Islet cell — tissue antigens — antibodies | AIC | 71109 |
insert
| Insulin — tissue antigens — antibodies | AINS | 71165 |
| Insulin receptor antibodies — tissue antigens — antibodies | INSA | 71165 |
| Intercellular cement substance of skin — tissue antigens — antibodies | ICCS | 71165 |
| Intestinal disaccharidases | INTD | 66680 |
| Intrinsic factor — tissue antigens — antibodies | AIF | 71165 |
| Iron studies (iron, transferrin and ferritin) | IS | 66596 |
| Islet cell — tissue antigens — antibodies | AIC | 71165 |
[70] Schedule 1, Part 4
omit
| Lupus anticoagulant | LUPA | 65132–37, 65142 |
insert
| Lupus anticoagulant | LUPA | 65137, 65142, 65175–79 |
[71] Schedule 1, Part 4
omit
| Lymphocyte — tissue antigens — antibodies | ALY | 71109 |
insert
| Lymphocyte — tissue antigens — antibodies | ALY | 71165 |
[72] Schedule 1, Part 4
omit
| Manganese | MN | 66669–70 |
insert
| Manganese | MN | 66819, 66822 |
[73] Schedule 1, Part 4
omit
| Mercury | HG | 66672–73 |
insert
| Mercury | HG | 66825, 66828 |
[74] Schedule 1, Part 4
omit
| Microbial antigen testing — Chlamydia | MCCH | 69364 |
| Microbial antigen testing — Clostridium difficile | CLDT | 69363 |
| Microbial antigen testing — group B streptococcus | STB | 69364 |
| Microbial antigen testing — Haemophilus influenzae | HI | 69364 |
| Microbial antigen testing — herpes simplex virus | HSV | 69364 |
| Microbial antigen testing — Neisseria gonorrhoeae | GON | 69364 |
| Microbial antigen testing — Neisseria meningitidis | NMG | 69364 |
| Microbial antigen testing — respiratory syncytial virus | RSVN | 69364 |
| Microbial antigen testing — Streptococcus pneumoniae | SPN | 69364 |
| Microbial antigen testing — Varicella zoster | VCZN | 69364 |
insert
| Microbial antigen testing — Chlamydia | MCCH | 69494 |
| Microbial antigen testing — Clostridium difficile | CLDT | 69363 |
| Microbial antigen testing — group B streptococcus | STB | 69494 |
| Microbial antigen testing — Haemophilus influenzae | HI | 69494 |
| Microbial antigen testing — herpes simplex virus | HSV | 69494 |
| Microbial antigen testing — Neisseria gonorrhoeae | GON | 69494 |
| Microbial antigen testing — Neisseria meningitidis | NMG | 69494 |
| Microbial antigen testing — respiratory syncytial virus | RSVN | 69494 |
| Microbial antigen testing — Streptococcus pneumoniae | SPN | 69494 |
| Microbial antigen testing — Varicella zoster | VCZN | 69494 |
[75] Schedule 1, Part 4
omit
| Microscopy and culture to detect pathogenic micro‑organisms including Chlamydia | MCCH | 69364 |
insert
| Microscopy and culture to detect pathogenic micro‑organisms including Chlamydia | MCCH | 69494 |
[76] Schedule 1, Part 4
omit
| Neisseria gonorrhoeae by NAA techniques and chlamydia by any method | CHGO | 69364 |
| Neisseria gonorrhoeae — microbial antigen testing | GON | 69364 |
| Neisseria meningitidis — antigens | NMG | 69364 |
| Neisseria meningitidis — microbial antibody testing | MEN | 69384 |
| Neisseria meningitidis — microbial antigen testing | NMG | 69364 |
insert
| Neisseria gonorrhoeae by NAA techniques and chlamydia by any method | CHGO | 69494 |
| Neisseria gonorrhoeae — microbial antigen testing | GON | 69494 |
| Neisseria meningitidis — antigens | NMG | 69494 |
| Neisseria meningitidis — microbial antibody testing | MEN | 69384 |
| Neisseria meningitidis — microbial antigen testing | NMG | 69494 |
[77] Schedule 1, Part 4
omit
| Neuron — tissue antigens — antibodies | ANE | 71109 |
| Neutrophil cytoplasm — tissue antigens — antibodies | ANCA | 71109 |
insert
| Neuron — tissue antigens — antibodies | ANE | 71165 |
| Neutrophil cytoplasm — tissue antigens — antibodies | ANCA | 71165 |
[78] Schedule 1, Part 4
omit
| Nickel | NI | 66672–73 |
insert
| Nickel | NI | 66825, 66828 |
[79] Schedule 1, Part 4
omit
| Ovary — tissue antigens — antibodies | AOV | 71109 |
insert
| Ovary — tissue antigens — antibodies | AOV | 71165 |
[80] Schedule 1, Part 4
omit
| Parathyroid — tissue antigens — antibodies | PTHA | 71109 |
insert
| Parathyroid — tissue antigens — antibodies | PTHA | 71165 |
[81] Schedule 1, Part 4
omit
| Patient episode initiation fees | PEI | 73901–15 |
insert
| Patient episode initiation fees | PEI | 73922–39 |
[82] Schedule 1, Part 4
omit
| Platelet — tissue antigens — antibodies | APA | 71109 |
insert
| Platelet — tissue antigens — antibodies | APA | 71165 |
[83] Schedule 1, Part 4
omit
| Protein — C | PROC | 65132–36, 65142, 65171 |
| Protein — S | PROS | 65132–36, 65142, 65171 |
insert
| Protein — C | PROC | 65142, 65171, 65175–79 |
| Protein — S | PROS | 65142, 65171, 65175–79 |
[84] Schedule 1, Part 4
omit
| Referred specimen fee | 73921 |
insert
| Referred specimen fee | 73940 |
[85] Schedule 1, Part 4
omit
| Respiratory syncytial virus — microbial antigen testing | RSVN | 69364 |
insert
| Respiratory syncytial virus — microbial antigen testing | RSVN | 69494 |
[86] Schedule 1, Part 4
omit
| RSV (respiratory syncytial virus) — microbial antigen testing | RSVN | 69364 |
insert
| RSV (respiratory syncytial virus) — microbial antigen testing | RSVN | 69494 |
[87] Schedule 1, Part 4
omit
| Salivary gland — tissue antigens — antibodies | ASG | 71109 |
insert
| Salivary gland — tissue antigens — antibodies | ASG | 71165 |
[88] Schedule 1, Part 4
omit
| Selenium | SE | 66669–70 |
insert
| Selenium | SE | 66819, 66822 |
[89] Schedule 1, Part 4
omit
| Skeletal muscle — tissue antigens — antibodies | SLA | 71109 |
insert
| Skeletal muscle — tissue antigens — antibodies | SLA | 71165 |
[90] Schedule 1, Part 4
omit
| Skin basement membrane — tissue antigens — antibodies | SKA | 71109 |
insert
| Skin basement membrane — tissue antigens — antibodies | SKA | 71165 |
[91] Schedule 1, Part 4
omit
| Specimen referred fee | 73921 |
insert
| Specimen referred fee | 73940 |
[92] Schedule 1, Part 4
omit
| Streptococcus — Group B | STB | 69364 |
| Streptococcus pneumoniae — CSF antigens | SPN | 69364 |
| Streptococcus pneumoniae — microbial antibody testing | PCC | 69384 |
| Streptococcus pneumoniae — microbial antigen testing | SPN | 69364 |
| Strontium | SR | 66672–73 |
insert
| Streptococcus — Group B | STB | 69494 |
| Streptococcus pneumoniae — CSF antigens | SPN | 69494 |
| Streptococcus pneumoniae — microbial antibody testing | PCC | 69384 |
| Streptococcus pneumoniae — microbial antigen testing | SPN | 69494 |
| Strontium | SR | 66825, 66828 |
[93] Schedule 1, Part 4
omit
| Thyroglobulin — tissue antigens — antibodies | ATG | 71109 |
| Thyroid function tests (including TSH) | TFT | 66719 |
| Thyroid microsome — tissue antigens — antibodies | TMA | 71109 |
insert
| Thyroglobulin — tissue antigens — antibodies | ATG | 71165 |
| Thyroid function tests (including TSH) | TFT | 66719 |
| Thyroid microsome — tissue antigens — antibodies | TMA | 71165 |
[94] Schedule 1, Part 4
omit
| TSH receptor antibody test — tissue antigens — antibodies | TSHA | 71109 |
insert
| TSH receptor antibody test — tissue antigens — antibodies | TSHA | 71165 |
[95] Schedule 1, Part 4
omit
| Varicella zoster — microbial antigen testing | VCZN | 69364 |
insert
| Varicella zoster — microbial antigen testing | VCZN | 69494 |
[96] Schedule 1, Part 5
omit
| Anus, neoplasm, radical resection | 6 |
insert
| Anus, neoplasm, radical resection | 6 |
| Anus, submucosal resection — neoplasm | 5 |
[97] Schedule 1, Part 5
omit
| Large bowel (including rectum), segmental resection, neoplasm | 6 |
insert
| Large bowel (including rectum), segmental resection — neoplasm | 6 |
| Large bowel (including rectum), submucosal resection — neoplasm | 5 |
[98] Schedule 1, Part 5
omit
| Oesophagus, partial or total resection | 6 |
insert
| Oesophagus, partial or total resection | 6 |
| Oesophagus, submucosal resection — neoplasm | 5 |
[99] Schedule 1, Part 5
omit
| Small bowel, resection — neoplasm | 6 |
insert
| Small bowel, resection — neoplasm | 6 |
| Small bowel, submucosal resection — neoplasm | 5 |
[100] Schedule 1, Part 5
omit
| Stomach, resection, neoplasm — all specimens | 6 |
insert
| Stomach, resection, neoplasm — all specimens | 6 |
| Stomach, submucosal resection — neoplasm | 5 |
Note
-
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. See
0
0
0